Relative Risks of Relapse, Treatment Failure, or Death after Allogeneic Bone Marrow Transplantation in First Remission
| . | Poor Prognostic Factor . | RR (95% CI) . | P . |
|---|---|---|---|
| Relapse | No aGVHD | 1.73 (1.35-2.22) | .02 |
| Short interval CR-BMT | 2.74 (1.67-4.41) | .006 | |
| Poor cytogenetics | 2.66 (1.65-4.30) | .00002 | |
| No a/cGVHD | 2.84 (1.23-6.38) | .00005 | |
| Short interval CR-BMT | 2.76 (1.56-4.84) | .003 | |
| Poor cytogenetics | 3.45 (1.97-6.04) | .000003 | |
| No cGVHD | 2.8 (0.65-12) | .04 | |
| Poor cytogenetics | 3.44 (1.89-6.26) | .00002 | |
| Treatment failure | No aGVHD | NS | |
| Poor cytogenetics | 1.86 (1.76-1.96) | .004 | |
| No a/cGVHD | 2.77 (1.87-4.09) | .0002 | |
| Poor cytogenetics | 2.51 (1.61-3.90) | .0001 | |
| No cGVHD | 2.76 (0.61-11.8) | .008 | |
| Poor cytogenetics | 2.46 (1.47-4.75) | .001 | |
| Death | No aGVHD | NS | |
| Age | 1.60 (1.35-1.89) | .004 | |
| Poor cytogenetics | 2.61 (1.25-2.79) | .005 | |
| No a/cGVHD | 2.73 (1.81-4.05) | .007 | |
| Poor cytogenetics | 2.52 (2.38-2.63) | .0002 | |
| No cGVHD | 2.75 (0.62-5.37) | .01 | |
| Poor cytogenetics | 2.25 (2.10-2.45) | .007 |
| . | Poor Prognostic Factor . | RR (95% CI) . | P . |
|---|---|---|---|
| Relapse | No aGVHD | 1.73 (1.35-2.22) | .02 |
| Short interval CR-BMT | 2.74 (1.67-4.41) | .006 | |
| Poor cytogenetics | 2.66 (1.65-4.30) | .00002 | |
| No a/cGVHD | 2.84 (1.23-6.38) | .00005 | |
| Short interval CR-BMT | 2.76 (1.56-4.84) | .003 | |
| Poor cytogenetics | 3.45 (1.97-6.04) | .000003 | |
| No cGVHD | 2.8 (0.65-12) | .04 | |
| Poor cytogenetics | 3.44 (1.89-6.26) | .00002 | |
| Treatment failure | No aGVHD | NS | |
| Poor cytogenetics | 1.86 (1.76-1.96) | .004 | |
| No a/cGVHD | 2.77 (1.87-4.09) | .0002 | |
| Poor cytogenetics | 2.51 (1.61-3.90) | .0001 | |
| No cGVHD | 2.76 (0.61-11.8) | .008 | |
| Poor cytogenetics | 2.46 (1.47-4.75) | .001 | |
| Death | No aGVHD | NS | |
| Age | 1.60 (1.35-1.89) | .004 | |
| Poor cytogenetics | 2.61 (1.25-2.79) | .005 | |
| No a/cGVHD | 2.73 (1.81-4.05) | .007 | |
| Poor cytogenetics | 2.52 (2.38-2.63) | .0002 | |
| No cGVHD | 2.75 (0.62-5.37) | .01 | |
| Poor cytogenetics | 2.25 (2.10-2.45) | .007 |
Relative risks are derived from multivariate Cox regression. At first, the model included age, FAB, time interval between diagnosis and complete remission, time interval between complete remission and BMT, WBC at diagnosis, and year of BMT. Subsequently, GVHD was examined for additional preditive power.
Abbreviations: RR, relative risk; CI, confidence interval; aGVHD, acute graft-versus-host disease; Int CR-BMT, time interval from complete remission to bone marrow transplantation; cGVHD, chronic GVHD; a/cGVHD, acute and chronic GVHD.